Partner Content Partner Content BioPharmaLogic, Antikor Biopharma and UCL Host 2 Must Attend... ADC Summit
Partner Content Partner Content Juergen Knoebel from Roche speaks at the High Potent Medicin... Insights on HPAPI manufacturing
Events Partner Content The High Potent Medicines Conference The manufacturing of high potent medicines has provided many challenges in terms of safe production, containment and handling due to their toxic nature.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.